VFA
AIMT

Virtus Fund Advisers’s Aimmune Therapeutics AIMT Stock Holding History

Virtus Fund Advisers’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$391K Buy
+10,336
New +$334K ﹤0.01% 363

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Virtus Fund Advisers's AIMT Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Aimmune Therapeutics (AIMT) in Q4 2017: 10,336 shares worth $391K. The stake represents ﹤0.01% of the portfolio and ranks #363 among its holdings.

129 funds tracked by Wall St. Rank hold AIMT as of Q4 2017.

  • Virtus Fund Advisers held 10,336 shares of Aimmune Therapeutics worth $391K as of Q4 2017.
  • Aimmune Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Aimmune Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #363 holding.
  • 129 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.